Sanuwave Health Inc. (NASDAQ:SNWV – Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 304,527 shares, a decline of 45.8% from the July 30th total of 561,489 shares. Currently, 4.1% of the shares of the company are short sold. Based on an average trading volume of 109,529 shares, the days-to-cover ratio is currently 2.8 days.
Institutional Investors Weigh In On Sanuwave Health
Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in shares of Sanuwave Health during the second quarter worth $26,000. BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health in the second quarter valued at $46,000. Russell Investments Group Ltd. purchased a new position in shares of Sanuwave Health in the third quarter valued at $67,000. New York State Common Retirement Fund bought a new stake in shares of Sanuwave Health during the 2nd quarter valued at $102,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Sanuwave Health during the 2nd quarter valued at $109,000. Institutional investors own 42.53% of the company’s stock.
Sanuwave Health Stock Performance
SNWV traded down $0.02 during trading hours on Monday, hitting $4.66. The stock had a trading volume of 25,281 shares, compared to its average volume of 123,499. Sanuwave Health has a 1 year low of $4.50 and a 1 year high of $42.75. The company’s fifty day simple moving average is $7.17 and its 200 day simple moving average is $14.64. The stock has a market cap of $40.07 million, a PE ratio of 19.42 and a beta of 1.48. The company has a quick ratio of 0.89, a current ratio of 1.28 and a debt-to-equity ratio of 4.87.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered shares of Sanuwave Health from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sanuwave Health presently has an average rating of “Moderate Buy” and an average target price of $51.00.
View Our Latest Analysis on Sanuwave Health
About Sanuwave Health
Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.
The company’s lead product, the dermaPACE® system, holds clearance from the U.S.
Further Reading
- Five stocks we like better than Sanuwave Health
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
- AST SpaceMobile Is Down 54%—Can FCC Progress and BlueBirds Reverse the Slide?
- Don’t Miss These 3 Companies Delivering Strong Guidance Updates
- Insider Confidence Is Building in These 3 Very Different Stocks
Receive News & Ratings for Sanuwave Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanuwave Health and related companies with MarketBeat.com's FREE daily email newsletter.
